Covered recipient · General Payments record
PETER J RUANE
Allopathic & Osteopathic Physicians Internal Medicine Infectious Disease
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$63,582.90
232 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $46,020.00 | 18 |
| Consulting Fee | $6,960.00 | 1 |
| Travel and Lodging | $5,890.19 | 22 |
| Food and Beverage | $4,637.72 | 190 |
| Education | $74.99 | 1 |
By paying entity
PY2019 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Gilead Sciences, Inc. | $38,753.41 | 80 |
| ViiV Healthcare Company | $23,395.32 | 72 |
| Janssen Biotech, Inc. | $274.29 | 18 |
| Amgen Inc. | $157.98 | 7 |
| Napo Pharmaceuticals Inc | $149.65 | 10 |
| Allergan Inc. | $120.88 | 5 |
| Merck Sharp & Dohme Corporation | $113.31 | 7 |
| Amarin Pharma Inc. | $81.69 | 4 |
| Antares Pharma, Inc. | $81.55 | 5 |
| Theratechnologies Inc. | $80.33 | 5 |
| Janssen Products, LP | $74.99 | 1 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $59.13 | 4 |
| Takeda Pharmaceuticals U.S.A., Inc. | $48.97 | 3 |
| GlaxoSmithKline, LLC. | $48.87 | 3 |
| Janssen Scientific Affairs, LLC | $44.64 | 2 |
| SANOFI PASTEUR INC. | $37.08 | 2 |
| Mylan Institutional Inc. | $27.82 | 2 |
| AbbVie, Inc. | $20.81 | 1 |
| Vyera Pharmaceuticals, LLC | $12.18 | 1 |
Page 3 of 5; records 101–150 of 232 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
PETER J RUANE
NPI 1467640953 · CMS profile ID 339520
Allopathic & Osteopathic Physicians / Internal Medicine / Infectious Disease
LOS ANGELES, CA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 5; records 101–150 of 232 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1467640953?year=2019&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- PETER J RUANE, NPI 1467640953, CMS profile ID 339520. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 232 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1467640953?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). PETER J RUANE, NPI 1467640953, CMS profile ID 339520. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 232 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1467640953?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- PETER J RUANE, NPI 1467640953, CMS profile ID 339520, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 5; records 101–150 of 232 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1467640953?year=2019&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
232 matching records · $63,582.90 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–150 of 232.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| ViiV Healthcare Company | $16.59 | 07/12/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671589359 | CMS |
| Antares Pharma, Inc. | $15.37 | 07/11/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 676459439 | CMS |
| Theratechnologies Inc. | $18.82 | 07/11/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 703941989 | CMS |
| Janssen Biotech, Inc. | $15.14 | 07/09/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658681897 | CMS |
| ViiV Healthcare Company | $3,600.00 | 07/08/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671594375 | CMS |
| SANOFI PASTEUR INC. | $19.89 | 07/03/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 691601823 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $20.96 | 06/28/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 682074815 | CMS |
| Gilead Sciences, Inc. | $20.94 | 06/19/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681595115 | CMS |
| Janssen Biotech, Inc. | $10.80 | 06/18/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658681893 | CMS |
| ViiV Healthcare Company | $0.12 | 06/17/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671588019 | CMS |
| ViiV Healthcare Company | $16.22 | 06/15/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671568439 | CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $12.80 | 06/14/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 684914059 | CMS |
| Merck Sharp & Dohme Corporation | $14.90 | 06/13/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695676689 | CMS |
| Gilead Sciences, Inc. | $8.70 | 06/12/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 679354356 | CMS |
| ViiV Healthcare Company | $14.76 | 06/12/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671569577 | CMS |
| ViiV Healthcare Company | $0.19 | 06/12/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671596951 | CMS |
| Gilead Sciences, Inc. | $11.60 | 06/10/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 679354353 | CMS |
| Gilead Sciences, Inc. | $1.18 | 06/10/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681595111 | CMS |
| Gilead Sciences, Inc. | $21.76 | 06/10/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681595113 | CMS |
| Gilead Sciences, Inc. | $0.82 | 06/09/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681595109 | CMS |
| Gilead Sciences, Inc. | $6,960.00 | 06/07/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 679262997 | CMS |
| Gilead Sciences, Inc. | $2,500.00 | 06/06/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 679316941 | CMS |
| Gilead Sciences, Inc. | $20.67 | 06/05/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681595107 | CMS |
| Gilead Sciences, Inc. | $110.57 | 06/04/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681595105 | CMS |
| Janssen Biotech, Inc. | $14.66 | 06/04/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658681889 | CMS |
| Gilead Sciences, Inc. | $183.30 | 05/31/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 679354345 | CMS |
| Gilead Sciences, Inc. | $358.78 | 05/31/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 679354347 | CMS |
| Gilead Sciences, Inc. | $669.05 | 05/31/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 679354349 | CMS |
| Gilead Sciences, Inc. | $7.83 | 05/31/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681595097 | CMS |
| Gilead Sciences, Inc. | $18.00 | 05/31/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681595099 | CMS |
| Gilead Sciences, Inc. | $26.90 | 05/31/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681595101 | CMS |
| Gilead Sciences, Inc. | $125.00 | 05/31/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681595103 | CMS |
| ViiV Healthcare Company | $1,000.00 | 05/31/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671571483 | CMS |
| Gilead Sciences, Inc. | $2,500.00 | 05/30/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 679316939 | CMS |
| Gilead Sciences, Inc. | $107.29 | 05/30/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 679354339 | CMS |
| Gilead Sciences, Inc. | $280.94 | 05/30/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 679358835 | CMS |
| Gilead Sciences, Inc. | $120.39 | 05/30/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681595095 | CMS |
| Gilead Sciences, Inc. | $408.49 | 05/29/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 679358801 | CMS |
| Gilead Sciences, Inc. | $47.81 | 05/24/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681595093 | CMS |
| Janssen Biotech, Inc. | $13.31 | 05/24/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658681885 | CMS |
| Gilead Sciences, Inc. | $21.33 | 05/22/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681595091 | CMS |
| Gilead Sciences, Inc. | $2,450.00 | 05/21/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 679316933 | CMS |
| Merck Sharp & Dohme Corporation | $18.30 | 05/21/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695480731 | CMS |
| ViiV Healthcare Company | $19.91 | 05/20/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671589609 | CMS |
| ViiV Healthcare Company | $0.37 | 05/20/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671606947 | CMS |
| ViiV Healthcare Company | $0.22 | 05/20/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671608987 | CMS |
| Gilead Sciences, Inc. | $3.43 | 05/15/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681595087 | CMS |
| Gilead Sciences, Inc. | $24.41 | 05/15/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681595089 | CMS |
| Gilead Sciences, Inc. | $26.14 | 05/14/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681595085 | CMS |
| Napo Pharmaceuticals Inc | $13.15 | 05/14/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 702236451 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $839,319.25 | 78 |
| PY2024 | Principal investigator | $555,730.94 | 61 |
| PY2023 | Recipient | $3,037.89 | 9 |
| PY2023 | Principal investigator | $1,163,506.79 | 108 |
| PY2022 | Principal investigator | $936,049.26 | 93 |
| PY2021 | Principal investigator | $5,365,430.63 | 154 |
| PY2020 | Principal investigator | $8,530,897.87 | 212 |
| PY2019 | Recipient | $22,149.32 | 11 |
| PY2019 | Principal investigator | $7,010,079.61 | 214 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
78 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Merck Sharp & Dohme LLC | $3.67 | 12/31/2025 | Non-covered Recipient Entity Ruane Clinical Research Group, Inc. | A Phase 2,3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MK-4482 in Non-Hospitalized Adults with COVID-19. | No dispute reported | 06/30/2026 | 1232928878 |
| Principal investigator 1 | Gilead Sciences, Inc. | $2,312.00 | 12/23/2025 | Non-covered Recipient Entity RUANE CLINICAL RESEARCH GROUP | A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection | No dispute reported | 06/30/2026 | 1229220224 |
| Principal investigator 1 | Gilead Sciences, Inc. | $8,928.00 | 12/23/2025 | Non-covered Recipient Entity RUANE CLINICAL RESEARCH GROUP | A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection | No dispute reported | 06/30/2026 | 1229220231 |
| Principal investigator 1 | Gilead Sciences, Inc. | $3,600.00 | 12/23/2025 | Non-covered Recipient Entity RUANE CLINICAL RESEARCH GROUP | A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection | No dispute reported | 06/30/2026 | 1229220240 |
| Principal investigator 1 | Gilead Sciences, Inc. | $1,759.46 | 12/23/2025 | Non-covered Recipient Entity RUANE CLINICAL RESEARCH GROUP | A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection | No dispute reported | 06/30/2026 | 1229220251 |
| Principal investigator 1 | Gilead Sciences, Inc. | $2,493.00 | 12/16/2025 | Non-covered Recipient Entity RUANE CLINICAL RESEARCH GROUP | Acceptability of Long-Acting Injectable Lenacapavir Versus Oral Emtricitabine/Tenofovir Disoproxil Fumarate for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Nonbinary People: Qualitative Insights Into Social and Behavioral Contexts | No dispute reported | 06/30/2026 | 1229215219 |
| Principal investigator 1 | ABBVIE INC. | $7,340.12 | 12/10/2025 | Non-covered Recipient Entity RUANE CLINICAL RESEARCH GROUP INC | A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 | No dispute reported | 06/30/2026 | 1202529894 |
| Principal investigator 1 | Gilead Sciences, Inc. | $300.00 | 12/09/2025 | Non-covered Recipient Entity RUANE CLINICAL RESEARCH GROUP | Acceptability of Long-Acting Injectable Lenacapavir Versus Oral Emtricitabine/Tenofovir Disoproxil Fumarate for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Nonbinary People: Qualitative Insights Into Social and Behavioral Contexts | No dispute reported | 06/30/2026 | 1229215209 |
| Principal investigator 1 | Gilead Sciences, Inc. | $3,450.00 | 12/09/2025 | Non-covered Recipient Entity RUANE CLINICAL RESEARCH GROUP | A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection | No dispute reported | 06/30/2026 | 1229220212 |
| Principal investigator 1 | Gilead Sciences, Inc. | $775.00 | 11/21/2025 | Non-covered Recipient Entity RUANE CLINICAL RESEARCH GROUP | Acceptability of Long-Acting Injectable Lenacapavir Versus Oral Emtricitabine/Tenofovir Disoproxil Fumarate for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Nonbinary People: Qualitative Insights Into Social and Behavioral Contexts | No dispute reported | 06/30/2026 | 1229215198 |
| Principal investigator 1 | ViiV Healthcare Company | $42,312.33 | 11/19/2025 | Non-covered Recipient Entity LOUISIANA STATE UNIVERSITY HEALTH SCIENCE CENTER | A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET | No dispute reported | 06/30/2026 | 1190317123 |
| Principal investigator 1 | ViiV Healthcare Company | $64,850.52 | 10/28/2025 | Non-covered Recipient Entity RUANE CLINICAL RESEARCH GROUP INC | A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET | No dispute reported | 06/30/2026 | 1190316985 |
| Principal investigator 1 | Gilead Sciences, Inc. | $6,872.00 | 10/21/2025 | Non-covered Recipient Entity RUANE CLINICAL RESEARCH GROUP | A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection | No dispute reported | 06/30/2026 | 1229220203 |
| Principal investigator 1 | ViiV Healthcare Company | $575.50 | 10/10/2025 | Non-covered Recipient Entity RUANE CLINICAL RESEARCH GROUP INC | A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET | No dispute reported | 06/30/2026 | 1190314597 |
| Principal investigator 1 | ViiV Healthcare Company | $968.03 | 10/10/2025 | Non-covered Recipient Entity RUANE CLINICAL RESEARCH GROUP INC | A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET | No dispute reported | 06/30/2026 | 1190314609 |
| Principal investigator 1 | ViiV Healthcare Company | $712.04 | 10/10/2025 | Non-covered Recipient Entity RUANE CLINICAL RESEARCH GROUP INC | A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET | No dispute reported | 06/30/2026 | 1190316259 |
| Principal investigator 1 | ViiV Healthcare Company | $1,155.35 | 10/10/2025 | Non-covered Recipient Entity RUANE CLINICAL RESEARCH GROUP INC | A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET | No dispute reported | 06/30/2026 | 1190316989 |
| Principal investigator 1 | ViiV Healthcare Company | $465.63 | 10/10/2025 | Non-covered Recipient Entity RUANE CLINICAL RESEARCH GROUP INC | A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET | No dispute reported | 06/30/2026 | 1190317115 |
| Principal investigator 1 | ViiV Healthcare Company | $74.85 | 10/10/2025 | Non-covered Recipient Entity RUANE CLINICAL RESEARCH GROUP INC | A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET | No dispute reported | 06/30/2026 | 1190319073 |
| Principal investigator 1 | ViiV Healthcare Company | $47.86 | 10/10/2025 | Non-covered Recipient Entity RUANE CLINICAL RESEARCH GROUP INC | A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET | No dispute reported | 06/30/2026 | 1190319079 |
| Principal investigator 1 | ViiV Healthcare Company | $669.58 | 10/10/2025 | Non-covered Recipient Entity RUANE CLINICAL RESEARCH GROUP INC | A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET | No dispute reported | 06/30/2026 | 1190319081 |
| Principal investigator 1 | ViiV Healthcare Company | $53,435.20 | 09/10/2025 | Non-covered Recipient Entity RUANE CLINICAL RESEARCH GROUP INC | A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET | No dispute reported | 06/30/2026 | 1190316983 |
| Principal investigator 1 | Gilead Sciences, Inc. | $3,436.00 | 08/19/2025 | Non-covered Recipient Entity RUANE CLINICAL RESEARCH GROUP | A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection | No dispute reported | 06/30/2026 | 1229220190 |
| Principal investigator 1 | ViiV Healthcare Company | $69,931.26 | 08/15/2025 | Non-covered Recipient Entity RUANE CLINICAL RESEARCH GROUP INC | A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET | No dispute reported | 06/30/2026 | 1190314603 |
| Principal investigator 1 | ViiV Healthcare Company | $2,800.00 | 07/28/2025 | Non-covered Recipient Entity RUANE CLINICAL RESEARCH GROUP INC | A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET | No dispute reported | 06/30/2026 | 1190314607 |
| Principal investigator 1 | ViiV Healthcare Company | $150.00 | 07/28/2025 | Non-covered Recipient Entity RUANE CLINICAL RESEARCH GROUP INC | A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET | No dispute reported | 06/30/2026 | 1190314611 |
| Principal investigator 1 | ViiV Healthcare Company | $200.00 | 07/28/2025 | Non-covered Recipient Entity RUANE CLINICAL RESEARCH GROUP INC | A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET | No dispute reported | 06/30/2026 | 1190316251 |
| Principal investigator 1 | ViiV Healthcare Company | $200.00 | 07/28/2025 | Non-covered Recipient Entity RUANE CLINICAL RESEARCH GROUP INC | A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET | No dispute reported | 06/30/2026 | 1190316253 |
| Principal investigator 1 | ViiV Healthcare Company | $900.00 | 07/28/2025 | Non-covered Recipient Entity RUANE CLINICAL RESEARCH GROUP INC | A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET | No dispute reported | 06/30/2026 | 1190316257 |
| Principal investigator 1 | ViiV Healthcare Company | $450.00 | 07/28/2025 | Non-covered Recipient Entity RUANE CLINICAL RESEARCH GROUP INC | A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET | No dispute reported | 06/30/2026 | 1190316263 |
| Principal investigator 1 | ViiV Healthcare Company | $3,200.00 | 07/28/2025 | Non-covered Recipient Entity RUANE CLINICAL RESEARCH GROUP INC | A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET | No dispute reported | 06/30/2026 | 1190316265 |
| Principal investigator 1 | ViiV Healthcare Company | $3,000.00 | 07/28/2025 | Non-covered Recipient Entity RUANE CLINICAL RESEARCH GROUP INC | A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET | No dispute reported | 06/30/2026 | 1190317113 |
| Principal investigator 1 | ViiV Healthcare Company | $880.00 | 07/28/2025 | Non-covered Recipient Entity RUANE CLINICAL RESEARCH GROUP INC | A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET | No dispute reported | 06/30/2026 | 1190317117 |
| Principal investigator 1 | ViiV Healthcare Company | $1,040.00 | 07/28/2025 | Non-covered Recipient Entity RUANE CLINICAL RESEARCH GROUP INC | A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET | No dispute reported | 06/30/2026 | 1190319075 |
| Principal investigator 1 | ViiV Healthcare Company | $40.00 | 07/28/2025 | Non-covered Recipient Entity RUANE CLINICAL RESEARCH GROUP INC | A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET | No dispute reported | 06/30/2026 | 1190319083 |
| Principal investigator 1 | ViiV Healthcare Company | $2,550.00 | 07/28/2025 | Non-covered Recipient Entity RUANE CLINICAL RESEARCH GROUP INC | A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET | No dispute reported | 06/30/2026 | 1190319085 |
| Principal investigator 1 | Gilead Sciences, Inc. | $11,083.00 | 07/22/2025 | Non-covered Recipient Entity RUANE CLINICAL RESEARCH GROUP | A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection | No dispute reported | 06/30/2026 | 1229220180 |
| Principal investigator 1 | ViiV Healthcare Company | $51,108.09 | 07/14/2025 | Non-covered Recipient Entity RUANE CLINICAL RESEARCH GROUP INC | A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET | No dispute reported | 06/30/2026 | 1190319091 |
| Principal investigator 1 | ViiV Healthcare Company | $3,850.00 | 07/10/2025 | Non-covered Recipient Entity RUANE CLINICAL RESEARCH GROUP INC | A PHASE 3B, OPEN LABEL, RANDOMIZED, STANDARD-OF-CARE CONTROL ARM, MULT | No dispute reported | 06/30/2026 | 1190317111 |
| Principal investigator 1 | ViiV Healthcare Company | $2,200.00 | 07/10/2025 | Non-covered Recipient Entity RUANE CLINICAL RESEARCH GROUP INC | A PHASE 3B, OPEN LABEL, RANDOMIZED, STANDARD-OF-CARE CONTROL ARM, MULT | No dispute reported | 06/30/2026 | 1190319095 |
| Principal investigator 1 | ViiV Healthcare Company | $22,102.92 | 06/24/2025 | Non-covered Recipient Entity RUANE CLINICAL RESEARCH GROUP INC | A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET | No dispute reported | 06/30/2026 | 1190319077 |
| Principal investigator 1 | ViiV Healthcare Company | $215,822.67 | 06/18/2025 | Non-covered Recipient Entity RUANE CLINICAL RESEARCH GROUP INC | A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET | No dispute reported | 06/30/2026 | 1190314601 |
| Principal investigator 1 | ViiV Healthcare Company | $38,470.19 | 04/28/2025 | Non-covered Recipient Entity RUANE CLINICAL RESEARCH GROUP INC | A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET | No dispute reported | 06/30/2026 | 1190314599 |
| Principal investigator 1 | ViiV Healthcare Company | $13,953.50 | 04/28/2025 | Non-covered Recipient Entity RUANE CLINICAL RESEARCH GROUP INC | A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET | No dispute reported | 06/30/2026 | 1190316987 |
| Principal investigator 1 | Gilead Sciences, Inc. | $5,985.00 | 04/22/2025 | Non-covered Recipient Entity RUANE CLINICAL RESEARCH GROUP | A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection | No dispute reported | 06/30/2026 | 1229220172 |
| Principal investigator 1 | Gilead Sciences, Inc. | $8,500.00 | 04/08/2025 | Non-covered Recipient Entity RUANE CLINICAL RESEARCH GROUP | Acceptability of Long-Acting Injectable Lenacapavir Versus Oral Emtricitabine/Tenofovir Disoproxil Fumarate for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Nonbinary People: Qualitative Insights Into Social and Behavioral Contexts | No dispute reported | 06/30/2026 | 1229215189 |
| Principal investigator 1 | ABBVIE INC. | $4,575.52 | 04/03/2025 | Non-covered Recipient Entity RUANE CLINICAL RESEARCH GROUP INC | A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 | No dispute reported | 06/30/2026 | 1202472182 |
| Principal investigator 1 | Gilead Sciences, Inc. | $3,466.00 | 04/01/2025 | Non-covered Recipient Entity RUANE CLINICAL RESEARCH GROUP | Acceptability of Long-Acting Injectable Lenacapavir Versus Oral Emtricitabine/Tenofovir Disoproxil Fumarate for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Nonbinary People: Qualitative Insights Into Social and Behavioral Contexts | No dispute reported | 06/30/2026 | 1229215174 |
| Principal investigator 1 | ViiV Healthcare Company | $37,402.08 | 03/26/2025 | Non-covered Recipient Entity RUANE CLINICAL RESEARCH GROUP INC | A PHASE IIIB, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, NON-INFERIORITY | No dispute reported | 06/30/2026 | 1190317109 |
| Principal investigator 1 | ViiV Healthcare Company | $2,009.48 | 03/26/2025 | Non-covered Recipient Entity RUANE CLINICAL RESEARCH GROUP INC | A PHASE IIIB, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, NON-INFERIORITY | No dispute reported | 06/30/2026 | 1190319089 |
| Principal investigator 1 | ViiV Healthcare Company | $10,000.00 | 03/21/2025 | Non-covered Recipient Entity RUANE CLINICAL RESEARCH GROUP INC | A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET | No dispute reported | 06/30/2026 | 1190316261 |
| Principal investigator 1 | ViiV Healthcare Company | $3,800.00 | 03/21/2025 | Non-covered Recipient Entity RUANE CLINICAL RESEARCH GROUP INC | A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET | No dispute reported | 06/30/2026 | 1190316997 |
| Principal investigator 1 | ViiV Healthcare Company | $2,000.00 | 03/21/2025 | Non-covered Recipient Entity RUANE CLINICAL RESEARCH GROUP INC | A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET | No dispute reported | 06/30/2026 | 1190319087 |
| Principal investigator 1 | ViiV Healthcare Company | $2,500.00 | 03/21/2025 | Non-covered Recipient Entity RUANE CLINICAL RESEARCH GROUP INC | A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET | No dispute reported | 06/30/2026 | 1190319093 |
| Principal investigator 1 | ViiV Healthcare Company | $2,000.00 | 03/21/2025 | Non-covered Recipient Entity RUANE CLINICAL RESEARCH GROUP INC | A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET | No dispute reported | 06/30/2026 | 1190319099 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,650.00 | 03/20/2025 | Non-covered Recipient Entity RUANE CLINICAL RESEARCH GROUP INC | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248241146 |
| Principal investigator 1 | ViiV Healthcare Company | $9,668.00 | 03/20/2025 | Non-covered Recipient Entity RUANE CLINICAL RESEARCH GROUP INC | CAPTIVATE (CAB LA FOR PREP UTILIZATION OUTCOMES EXPERIENCE) | No dispute reported | 06/30/2026 | 1190317119 |
| Principal investigator 1 | Gilead Sciences, Inc. | $3,436.00 | 03/18/2025 | Non-covered Recipient Entity RUANE CLINICAL RESEARCH GROUP | A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection | No dispute reported | 06/30/2026 | 1229220159 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $168.00 | 03/06/2025 | Non-covered Recipient Entity RUANE CLINICAL RESEARCH GROUP INC | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248240171 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,268.22 | 03/06/2025 | Non-covered Recipient Entity RUANE CLINICAL RESEARCH GROUP INC | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248240175 |
| Principal investigator 1 | ViiV Healthcare Company | $1,474.00 | 03/06/2025 | Non-covered Recipient Entity RUANE CLINICAL RESEARCH GROUP INC | A PHASE 4, RANDOMIZED, OPEN-LABEL, TWO-ARM STUDY EVALUATING IMPLEMENTA | No dispute reported | 06/30/2026 | 1190317121 |
| Principal investigator 1 | ViiV Healthcare Company | $2,200.00 | 03/05/2025 | Non-covered Recipient Entity RUANE CLINICAL RESEARCH GROUP INC | A PHASE 3B, OPEN LABEL, RANDOMIZED, STANDARD-OF-CARE CONTROL ARM, MULT | No dispute reported | 06/30/2026 | 1190314605 |
| Principal investigator 1 | ViiV Healthcare Company | $3,850.00 | 03/05/2025 | Non-covered Recipient Entity RUANE CLINICAL RESEARCH GROUP INC | A PHASE 3B, OPEN LABEL, RANDOMIZED, STANDARD-OF-CARE CONTROL ARM, MULT | No dispute reported | 06/30/2026 | 1190316991 |
| Principal investigator 1 | Gilead Sciences, Inc. | $9,388.00 | 02/19/2025 | Non-covered Recipient Entity RUANE CLINICAL RESEARCH GROUP | A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection | No dispute reported | 06/30/2026 | 1229220149 |
| Principal investigator 1 | Gilead Sciences, Inc. | $14,880.00 | 02/18/2025 | Non-covered Recipient Entity RUANE CLINICAL RESEARCH GROUP | A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection | No dispute reported | 06/30/2026 | 1229220117 |
| Principal investigator 1 | Gilead Sciences, Inc. | $1,859.00 | 02/18/2025 | Non-covered Recipient Entity RUANE CLINICAL RESEARCH GROUP | A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection | No dispute reported | 06/30/2026 | 1229220127 |
| Principal investigator 1 | Gilead Sciences, Inc. | $4,181.02 | 02/18/2025 | Non-covered Recipient Entity RUANE CLINICAL RESEARCH GROUP | A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection | No dispute reported | 06/30/2026 | 1229220139 |
| Principal investigator 1 | ViiV Healthcare Company | $3,250.00 | 02/07/2025 | Non-covered Recipient Entity RUANE CLINICAL RESEARCH GROUP INC | A PHASE 3B, OPEN LABEL, RANDOMIZED, STANDARD-OF-CARE CONTROL ARM, MULT | No dispute reported | 06/30/2026 | 1190316255 |
| Principal investigator 1 | ViiV Healthcare Company | $14,000.00 | 02/07/2025 | Non-covered Recipient Entity RUANE CLINICAL RESEARCH GROUP INC | A PHASE 3B, OPEN LABEL, RANDOMIZED, STANDARD-OF-CARE CONTROL ARM, MULT | No dispute reported | 06/30/2026 | 1190316993 |
| Principal investigator 1 | ViiV Healthcare Company | $3,000.00 | 02/07/2025 | Non-covered Recipient Entity RUANE CLINICAL RESEARCH GROUP INC | A PHASE 3B, OPEN LABEL, RANDOMIZED, STANDARD-OF-CARE CONTROL ARM, MULT | No dispute reported | 06/30/2026 | 1190316995 |
| Principal investigator 1 | ViiV Healthcare Company | $1,000.00 | 02/07/2025 | Non-covered Recipient Entity RUANE CLINICAL RESEARCH GROUP INC | A PHASE 3B, OPEN LABEL, RANDOMIZED, STANDARD-OF-CARE CONTROL ARM, MULT | No dispute reported | 06/30/2026 | 1190319097 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,421.68 | 01/24/2025 | Non-covered Recipient Entity RUANE CLINICAL RESEARCH GROUP INC | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248238777 |
| Principal investigator 1 | Gilead Sciences, Inc. | $10,381.00 | 01/22/2025 | Non-covered Recipient Entity RUANE CLINICAL RESEARCH GROUP | A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection | No dispute reported | 06/30/2026 | 1229220108 |
| Principal investigator 1 | Ipsen Pharma SAS | $380.00 | 01/22/2025 | Non-covered Recipient Entity Ruane Clinical Research Group, Inc | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1184306985 |
| Principal investigator 1 | Ipsen Pharma SAS | $4,006.00 | 01/22/2025 | Non-covered Recipient Entity Ruane Clinical Research Group, Inc | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1184306987 |
| Principal investigator 1 | Ipsen Pharma SAS | $1,532.00 | 01/14/2025 | Non-covered Recipient Entity Ruane Clinical Research Group, Inc | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1184306983 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $13,045.30 | 01/13/2025 | Non-covered Recipient Entity RUANE CLINICAL RESEARCH GROUP INC | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248238391 |
| Principal investigator 1 | Gilead Sciences, Inc. | $575.18 | 01/07/2025 | Non-covered Recipient Entity RUANE CLINICAL RESEARCH GROUP | A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection | No dispute reported | 06/30/2026 | 1229220097 |